Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
BioTime Inc, Medical Devices Deals, 2011 to YTD 2017 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
BioTime Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
BioTime Completes Acquisition Of Stem Cell Assets From Geron 15
Venture Financing 18
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 18
Partnerships 19
BioTime and Hepregen Form Joint Venture 19
Asterias Biotherapeutics Enters into Agreement with Cell Therapy Catapult 20
BioTime Forms Joint Venture With XenneX 21
Licensing Agreements 22
Processa Pharma Enters into Licensing Agreement with BioTime 22
BioTime Enters into Licensing Agreement with Hadassah Medical 23
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 24
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 25
BioTime Enters Into Licensing Agreement With Cornell University 26
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 27
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 28
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 29
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 30
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 31
BioTime Enters Into Licensing Agreement With Jade Therapeutics For HyStem 32
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 33
Equity Offering 34
Asterias Biotherapeutics Raises USD10.4 Million in Private Placement of Shares 34
BioTime Completes Public Offering of Shares for USD28.8 Million 36
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 38
BioTime to Raise up to USD25 Million in Private Placement of Shares 40
Asterias Biotherapeutics to Raise up to USD25 Million in Public Offering of Shares 41
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 42
BioTime Raises USD20 Million in Public Offering of Shares 43
OncoCyte Raises USD7.3 Million in Private Placement of Units 45
OncoCyte Raises USD3.2 Million in Private Placement of Units 46
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 47
Asterias Biotherapeutics Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD20 Million 49
BioTime Raises USD5 Million in Private Placement of Shares 51
BioTime Raises USD20.4 Million in Private Placement of Shares 52
BioTime Raises USD8.6 Million in Private Placement of Shares 54
Asterias Biotherapeutics Announces Private Placement of shares for USD17.5 Million upon Exercise of Warrants 55
Asterias Biotherapeutics Completes Private Placement of Shares for USD11.7 Million upon Exercise of Warrants 56
Asterias Biotherapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 57
Asterias Biotherapeutics Raises USD4 Million in Private Placement of Shares 58
Asterias Biotherapeutics Raises USD1.5 Million in Public Offering of Shares 59
BioTime Raises USD29 Million in Private Placement of Shares 60
BioTime Completes Private Placement Of Shares For US$6.4 Million 62
BioTime Announces Public Offering Of Shares For Up To US$15 Million 63
BioTime Completes Public Offering Of Shares For US$3.5 Million 64
Asterias Biotherapeutics Files Registration Statement For Public Offering Of Units For Up To US$15 Million 65
BioTime Completes Private Placement Of Units For US$9 Million 66
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 67
BioTime Announces Private Placement Of Common Stock 69
OncoCyte Completes Private Placement Of Shares For US$10 Million 70
BioTime Completes Private Placement For US$3.6 Million 71
Embryome Sciences Completes Private Placement Of US$2.5 Million 72
Acquisition 73
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 73
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 75
OrthoCyte Completes Acquisition Of Glycosan BioSystems 77
BioTime Acquires Cell Targeting 79
BioTime Inc – Key Competitors 80
BioTime Inc – Key Employees 81
BioTime Inc – Locations And Subsidiaries 82
Head Office 82
Other Locations & Subsidiaries 82
Joint Venture 83
Recent Developments 84
Strategy And Business Planning 84
Apr 06, 2017: BioTime Forms New Subsidiary AgeX Therapeutics to Develop its Programs Focused on Human Aging 84
Financial Announcements 85
Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 85
Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 87
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 89
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 91
Nov 03, 2016: BioTime Reports Third Quarter Results and Recent Clinical Progress 94
Aug 09, 2016: BioTime Reports Second Quarter Results and Recent Corporate Accomplishments 96
May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 98
Government and Public Interest 101
Sep 18, 2017: BioTime Awarded Grant from the NIH 101
Other Significant Developments 102
Jun 19, 2017: Biotime Expands & Advances Ophthalmology Portfolio 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103
BioTime Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
BioTime Inc, Deals By Therapy Area, 2011 to YTD 2017 10
BioTime Inc, Medical Devices Deals, 2011 to YTD 2017 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
BioTime Completes Acquisition Of Stem Cell Assets From Geron 15
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 18
BioTime and Hepregen Form Joint Venture 19
Asterias Biotherapeutics Enters into Agreement with Cell Therapy Catapult 20
BioTime Forms Joint Venture With XenneX 21
Processa Pharma Enters into Licensing Agreement with BioTime 22
BioTime Enters into Licensing Agreement with Hadassah Medical 23
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 24
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 25
BioTime Enters Into Licensing Agreement With Cornell University 26
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 27
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 28
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 29
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 30
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 31
BioTime Enters Into Licensing Agreement With Jade Therapeutics For HyStem 32
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 33
Asterias Biotherapeutics Raises USD10.4 Million in Private Placement of Shares 34
BioTime Completes Public Offering of Shares for USD28.8 Million 36
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 38
BioTime to Raise up to USD25 Million in Private Placement of Shares 40
Asterias Biotherapeutics to Raise up to USD25 Million in Public Offering of Shares 41
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 42
BioTime Raises USD20 Million in Public Offering of Shares 43
OncoCyte Raises USD7.3 Million in Private Placement of Units 45
OncoCyte Raises USD3.2 Million in Private Placement of Units 46
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 47
Asterias Biotherapeutics Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD20 Million 49
BioTime Raises USD5 Million in Private Placement of Shares 51
BioTime Raises USD20.4 Million in Private Placement of Shares 52
BioTime Raises USD8.6 Million in Private Placement of Shares 54
Asterias Biotherapeutics Announces Private Placement of shares for USD17.5 Million upon Exercise of Warrants 55
Asterias Biotherapeutics Completes Private Placement of Shares for USD11.7 Million upon Exercise of Warrants 56
Asterias Biotherapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 57
Asterias Biotherapeutics Raises USD4 Million in Private Placement of Shares 58
Asterias Biotherapeutics Raises USD1.5 Million in Public Offering of Shares 59
BioTime Raises USD29 Million in Private Placement of Shares 60
BioTime Completes Private Placement Of Shares For US$6.4 Million 62
BioTime Announces Public Offering Of Shares For Up To US$15 Million 63
BioTime Completes Public Offering Of Shares For US$3.5 Million 64
Asterias Biotherapeutics Files Registration Statement For Public Offering Of Units For Up To US$15 Million 65
BioTime Completes Private Placement Of Units For US$9 Million 66
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 67
BioTime Announces Private Placement Of Common Stock 69
OncoCyte Completes Private Placement Of Shares For US$10 Million 70
BioTime Completes Private Placement For US$3.6 Million 71
Embryome Sciences Completes Private Placement Of US$2.5 Million 72
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 73
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 75
OrthoCyte Completes Acquisition Of Glycosan BioSystems 77
BioTime Acquires Cell Targeting 79
BioTime Inc, Key Competitors 80
BioTime Inc, Key Employees 81
BioTime Inc, Subsidiaries 82
BioTime Inc, Joint Venture 83
